Integral Announces Panel Presentation at ISPOR 2025
SAN FRANCISCO, May 07, 2025--(BUSINESS WIRE)--Integral, a leader in privacy-first data collaboration, today announced it will chair a panel discussion at the ISPOR 2025 Conference, May 13-16 in Montreal, QC, Canada. The session, "Accelerating Health Economics Research Through PETs," will bring together leaders in health economics, privacy technology and outcomes research to address how privacy-enhancing technologies (PETs) are transforming the speed and scale of health economics and outcomes research (HEOR) studies.
Timothy Nobles, chief product officer for Integral, will be joined by Christine Lee, head of health strategy and partnerships for AnalyticsIQ, and Kenzie Alexander, head of privacy solutions for Datavant's Life Sciences, Ecosystem, and Public Sector business, to explore practical implementation strategies that protect privacy for real-world evidence while maintaining research integrity.
"This session is a must-see for teams that utilize regulated data for HEOR," says Nobles. "We have two brilliant leaders in data analytics and privacy who will share their takes on how PETs can be leveraged to reduce compliance overhead and reidentification risk in multi-site studies. We'll also cover how teams can maintain research integrity while implementing privacy controls and guidance to leverage privacy-preserving analytics in novel ways."
Event Details:
Accelerating Health Economics Research Through PETs
ISPOR 2025 Conference, Montreal Convention Center, Room 520
Thursday, May 15, 2025, at 1:45 – 2:45 PM EST
To learn more about Integral, visit www.useintegral.com
About Integral
Integral provides automated privacy infrastructure that enables organizations to work with regulated data quickly and securely. Our platform streamlines the integration of diverse data sources for health economics research while maintaining the highest standards of privacy protection and regulatory compliance. By automating privacy workflows, we help research teams dramatically reduce time-to-insight while expanding the breadth of data available for analysis. www.useintegral.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250507201206/en/
Contacts
Innsena for Integral
integral@innsena.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 hours ago
- Business Wire
Hawaii American Water Granted New Rates by Hawaii Public Utilities Commission
HONOLULU--(BUSINESS WIRE)--The Hawaii Public Utilities Commission (HPUC) has approved new wastewater rates for Hawaii American Water's Hawaii Kai, Mauna Lani, and Waimea service areas. The company's rate request was filed on August 5, 2024, and was primarily driven by over $40 million in local infrastructure upgrades in all three districts. The new rates reinforce the company's commitment to replace aging infrastructure, provide safe and reliable service, comply with environmental regulations and support infrastructure improvements for treatment plants, collection systems and pump stations. 'We are committed to making necessary infrastructure investments that allow us to continue providing safe and reliable wastewater services, while also enhancing the systems for long-term sustainability, resiliency and environmental protection,' said Lee Mansfield, Senior Manager Operations, Hawaii American Water. 'Our approach to consistent and efficient investment balanced with managing costs helps us deliver reliable and affordable service to our customers.' New rates are expected to be effective in early August 2025. The typical single-family customer in Hawaii Kai will see a monthly rate increase of approximately $4. For our Big Island operations at Mauna Lani and Waimea the typical single-family customer will see a rate increase of approximately $18 to $25 per month. The last rate adjustments were September 2003 for Mauna Lani operations and January 2011 for Waimea operations. The company last filed a rate case for the Hawaii Kai system in 2021. Customers will receive information about the new rates on their Hawaii American Water bill. Information will also be available on the company's website under Customer Service Billing, Your Wastewater Rates. About American Water American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit and join American Water on LinkedIn, Facebook, X and Instagram. About Hawaii American Water Hawaii American Water, a subsidiary of American Water, provides high-quality wastewater services to approximately 30,000 people. AWK-IR
Business Wire
21 hours ago
- Business Wire
Securities Fraud Investigation Into Molina Healthcare, Inc. (MOH) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of Molina Healthcare, Inc. ('Molina' or the 'Company') (NYSE: MOH) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MOLINA HEALTHCARE, INC. (MOH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 7, 2025, Molina provided preliminary financial results for the second quarter 2025, including adjusted earnings for the quarter of approximately $5.50 per share. The Company also lowered its full year 2025 adjusted earning guidance by over 10% to $21.50 to $22.50 per share. On this news, Molina's stock price fell $6.97, or 2.9%, to close at $232.61 per share on July 7, 2025, thereby injuring investors. Then, on July 23, 2025, Molina released its second quarter 2025 financial results, including adjusted earnings per diluted share of $5.48, missing consensus estimates and prior guidance due in part to 'medical cost pressure due to continued utilization of behavioral health, pharmacy, and inpatient and outpatient services.' The Company also further reduced its full year 2025 guidance, stating that the updated guidance 'reflects new information gained in the quarterly closing process and implications for medical cost trend assumptions for the second half of the year.' On this news, Molina's stock price fell $32.03, or 16.8%, to close at $158.22, thereby injuring investors further. Contact Us To Participate or Learn More: If you purchased Molina securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
21 hours ago
- Business Wire
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement * Death was reported to health authorities * Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.
